TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01898078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib ECT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib ECT
Study: NCT02466542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Patients will receive regular general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol group
Description: Patients will receive regular general anesthesia plus esmolol infusion
Study: NCT03299062

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cytology and Immunohistochemistry
Description: Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cytology and Immunohistochemistry
Description: Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cytology and Immunohistochemistry
Description: Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
Study: NCT02480686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+PEG+RBV
Description: Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study: NCT01566786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
Study: NCT03770273

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sarilumab
Description: Sarilumab is a fully human anti-IL-6Rα monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04089774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA)
Description: Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
Study: NCT03360279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular balloon
Description: Randomization: to use regular balloon to treat stent graft restenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DCB (paclitaxel-coated balloon)
Description: Randomization: to use DCB (paclitaxel-coated balloon, Ranger, Boston-Scientific) to treat stent graft restenosis. The paclitaxel dose is 2 ug/mm2 delivered with the Ranger drug-coated balloon.
Study: NCT02829710

Intervention type: BEHAVIORAL
Intervention: Nurse-driven sedation protocol
Description: The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
Study: NCT02071160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
Study: NCT00901641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CogniFit Personal Coach®
Description: The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
Study: NCT03011853

Intervention type: PROCEDURE
Intervention: Non-invasive and/or invasive mechanical ventilation
Description: Use of Non-invasive and invasive mechanical ventilation, focussing particularly on the first respiratory support mode in ICU

Intervention type: PROCEDURE
Intervention: Non-invasive and/or invasive mechanical ventilation
Description: Use of Non-invasive and invasive mechanical ventilation, focussing particularly on the first respiratory support mode in ICU

Intervention type: PROCEDURE
Intervention: Non-invasive and/or invasive mechanical ventilation
Description: Use of Non-invasive and invasive mechanical ventilation, focussing particularly on the first respiratory support mode in ICU
Study: NCT01181882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil and Aspirin
Description: 4 grams of fish oil each day for 28 days and 81 mg aspirin
Study: NCT03991767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POP-UP electronic alert
Description: Implementation of the POP-UP electronic alert for all patients with eligibility criteria

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serology HIV
Description: Realization of HIV serology for included patients.
Study: NCT00134719

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenHibrix (Hib-MenCY-TT)
Description: One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenHibrix (Hib-MenCY-TT)
Description: One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix® Penta
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix® Penta
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix® Penta
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar®
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar®
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar®
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB®
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB®
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec®
Description: One intramuscular dose at 2, 4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R®II
Description: One subcutaneous dose at 12-15 months of age
Study: NCT03628261

Intervention type: DEVICE
Group type: OTHER
Intervention: Serious Game
Description: Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Serious Game
Description: Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
Study: NCT00134719

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R®II
Description: One subcutaneous dose at 12-15 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R®II
Description: One subcutaneous dose at 12-15 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax®
Description: One subcutaneous dose at 12 to 15 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax®
Description: One subcutaneous dose at 12 to 15 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax®
Description: One subcutaneous dose at 12 to 15 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PedvaxHIB®
Description: One intramuscular dose at 12 to 15 months of age
Study: NCT02961660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir
Description: Participants will receive odalasvir 25 mg tablet, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir
Description: Participants will receive odalasvir 25 mg tablet, orally.
Study: NCT03987048

Intervention type: OTHER
Intervention: Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.
Description: Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded.
Study: NCT02939391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT01794780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA based treatment: indacaterol
Description: LABA based treatment: indacaterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA based treatment: tiotropium
Description: LAMA based treatment: tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA based treatment: tiotropium
Description: LAMA based treatment: tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA based treatment: tiotropium
Description: LAMA based treatment: tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA/ICS based treatment: salmeterol/fluticasone
Description: LABA/ICS based treatment: salmeterol/fluticasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA/ICS based treatment: salmeterol/fluticasone
Description: LABA/ICS based treatment: salmeterol/fluticasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA/ICS based treatment: budesonide/formoterol
Description: LABA/ICS based treatment: budesonide/formoterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA/ICS based treatment: budesonide/formoterol
Description: LABA/ICS based treatment: budesonide/formoterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: theophylline based treatment
Description: theophylline based treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other treatment
Description: non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments
Study: NCT01400737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
Study: NCT04407377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: Study Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine Hydrochloride 10 MG
Description: Active Comparator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02934607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort pMDI with spacer device
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort pMDI with spacer device
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI without spacer device
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI without spacer device
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
Study: NCT01819792

Intervention type: OTHER
Group type: OTHER
Intervention: Multiplex respiratory viral PCR
Study: NCT03839602

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reducing CTV
Description: CTVs were delineated in line with tumor stage, i.e. tumor invasion.
Study: NCT02491541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Changchun Werersai
Description: A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Jilin Maifeng
Description: A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28
Study: NCT03628261

Intervention type: OTHER
Group type: OTHER
Intervention: physical therapy
Description: Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
Study: NCT02666599

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically.
Study: NCT04663672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Scent
Description: Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Scent
Description: Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
Study: NCT01924702

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive language therapy
Description: 2 weeks of daily computerized naming training, daily, 3 hours

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive language therapy
Description: 2 weeks of daily computerized naming training, daily, 3 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
Study: NCT03272269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solvent: alum hydroxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solvent: alum hydroxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solvent: alum hydroxide
Study: NCT03426982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Infusion dose of unfractionated heparin was adjusted by APTT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Infusion dose of unfractionated heparin was adjusted by anti-Xa
Study: NCT04001140

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhancement of emotion regulation skills
Description: Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
Study: NCT03690336

Intervention type: DRUG
Intervention: Nonacog beta pegol
Description: Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
Study: NCT02814331

Intervention type: DEVICE
Intervention: multimodal high-resolution EEG-NIRS

Intervention type: DEVICE
Intervention: multimodal high-resolution EEG-NIRS
Study: NCT04173208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplant
Description: Fecal microbial transplant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00704522

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.

Intervention type: DRUG
Intervention: Ribavirin (SCH 18908)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.

Intervention type: BEHAVIORAL
Intervention: Patient assistance program
Description: Assistance programs will be classified as follows:~1. Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~2. Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only.
Study: NCT06335901

Intervention type: DRUG
Intervention: Drug:Standard therapy
Description: Percutaneous coronary Intervention
Study: NCT03486145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fruit and vegetable juice supplement
Description: FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement.
Study: NCT04191083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: This group will perform motor imagery training on motor learning of different motor tasks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double time motor imagery
Description: This group will perform motor imagery training by doubling the intervention time to the motor imagery group on motor learning of various motor tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: This group will perform action observation training on motor learning of various motor tasks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: This group will watch a video of a landscape without the presence of people.
Study: NCT01413633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: single incision laparoscopic cholecystectomy
Study: NCT02475824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam®
Description: midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam®
Description: midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine (pethidine®)
Description: Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine (pethidine®)
Description: Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol®
Description: Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Precedex®)
Description: Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
Study: NCT01302977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal tracheal occlusion
Description: Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy